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OBJECTIVES: To prospectively evaluate the long-term
societal economic and humanistic benefits of acute treat-
ment of AECB with gemifloxacin compared with
clarithromycin. METHODS: Patients with AECB were
randomized to receive acute, double-blind, double-
dummy treatment with either gemifloxacin 320 mg o.d.
for 5 days or clarithromycin 500 mg b.d. for 7 days. Pa-
tients in US (n  386) and Canadian centers (n  52)
were followed for 26 weeks from treatment initiation and
the following assessments were made: AECB recurrence
requiring antibiotic treatment; respiratory tract infection-
related: health care resource utilization, time off and per-
formance at work and usual activities; and health-related
quality of life using the St George’s Respiratory Ques-
tionnaire (SGRQ). RESULTS: In full sample analysis, sig-
nificantly more patients who received gemifloxacin re-
mained recurrence free after 26 weeks (73.8% [158/214]
vs. 63.8% [143/224]; p  0.024) and were hospitalized
less (2.34% [5/214] vs. 6.25% [14/224]; p  0.059).
Cost-effectiveness analysis indicated average direct and
indirect cost savings of $329 per patient for gemifloxacin
vs. clarithromycin. Ninety-five percent confidence inter-
vals for bootstrapped incremental cost-effectiveness ra-
tios ranged from a cost saving of $14,175 to a cost of
$8,888 per recurrence-free patient considering all costs.
There was an 82.5% probability of gemifloxacin being
both cost saving and more effective than clarithromycin
from the societal perspective. A greater improvement in
total weighted SGRQ score (lower scores being better),
adjusted for baseline, was observed for gemifloxacin vs.
clarithromycin at 4, 12 and 26 weeks after initiation of
acute treatment (43.3 vs. 44.6 [p  0.38], 39.4 vs. 41.8
[p  0.20] and 37.7 vs. 41.0 [p  0.09], respectively).
There was significantly less impact on performance at
work (p  0.01) and usual activities (p  0.03) at 26
weeks, due to bronchitis, among patients who received
gemifloxacin. CONCLUSIONS: Gemifloxacin was very
cost-effective from the societal perspective and improved
long-term patient outcomes compared with clarithromy-
cin for the treatment of AECB.
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Severe and difficult to treat asthma patients represent a
small percentage of all asthmatics, yet they account for
much of the morbidity, mortality, and cost of the disease.
The factors that make this group of asthmatics difficult
to manage are poorly understood. OBJECTIVE: To es-
tablish a cohort of severe or difficult to treat asthmatics
to examine the relationships between features of asthma,
treatments and health outcomes using the Internet.
METHODS: This study, “An Observational Study of
The Epidemiology and Natural History of Asthma: Out-
comes and Treatment Regiments (TENOR),” is designed
to follow at least 5000 subjects for 3 years. Subjects 6
years or older with a diagnosis of asthma and considered
by their physician to have severe or difficult to treat
asthma are eligible for enrollment. Physicians and coordi-
nators will conduct biannual visits to collect data includ-
ing: health care utilization, days of work or school
missed, the asthma therapy assessment questionnaire
(ATAQ), asthma-related quality of life (AQLQ), medica-
tions, IgE level, and lung function. Data will be entered
onto a secure website. RESULTS: Subjects are being en-
rolled into the cohort from over 300 US pulmonologists
and allergists in managed care organizations, community
practices, and academic centers. All study sites have In-
ternet access. The TENOR website was built using Web-
CollectSM services and PhaseForward’s InFormTM ap-
plication. Built-in edit checks and an automatic electronic
audit trail ensure data accuracy and completeness. This
technology eliminates the need for paper case report
forms and improves data cleaning efficiency. CONCLU-
SIONS: TENOR provides a unique opportunity to exam-
ine factors related to poor health outcomes in this under-
studied patient population. The Internet allows real time
access to data and facilitates dissemination of data to in-
vestigators and the asthma community. TENOR may
serve as a model for future large epidemiologic or clinical
studies using web-based technology.
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OBJECTIVE: Despite increased use in the health care
sector (HCS), the contingent valuation (CV) method re-
mains controversial. The nucleus of the controversy is the
extent to which hypothetical choices in the CV method
mimic real economic choices. Correspondence between
hypothetical and real willingness to pay (WTP) has been
studied for private and environmental goods. These ex-
periments demonstrate that dichotomous choice (DC)
CV questions lead to hypothetical bias (overestimation of
real WTP). Hypothetical bias has not been assessed in the
HCS. We conducted an experiment directly comparing
responses to a DC CV question with real purchase deci-
sions using a pharmacist provided asthma management
